Lev Facher

Washington Correspondent

Lev Facher is a Washington Correspondent for STAT, reporting on the politics of health and life sciences. He has written extensively about the federal government's response to the opioid crisis, the pharmaceutical industry's influence on Capitol Hill, and federally funded biomedical research. Lev earned an economics degree from the University of Michigan, where he worked as managing editor of The Michigan Daily. You can reach him via email at lev.facher@statnews.com and by phone/WhatsApp/Signal at (510)-374-8880.

Politics

Facing progressive pressure, Pelosi could expand her drug pricing plan to negotiate prices for $118 billion worth of medicines

By Lev Facher

Politics

Lev Facher

Washington Correspondent

Elizabeth Warren blasts former FDA commissioner for joining Pfizer’s board

What the Democrats said about ‘big pharma’ — and why it matters

In first 2020 debate, Democrats escalate their attacks on pharma and its high prices

Senate committee votes to force drug companies to justify major price increases

In a nationwide first, New Jersey authorizes paramedics to start addiction treatment at the scene of an overdose

It’s a big week for debates about drug prices, whether pharma likes it or not

VA declines broad coverage for new J&J depression drug touted by Trump

Pharma CEOs didn’t show up for a congressional scolding, so progressives shadowboxed instead

Biden wants to cure cancer. Now Trump does, too. But cancer, like health care, is complicated

Why Democrats reopened the debate about germline gene editing

Amgen, Merck, and Eli Lilly sue over Trump administration policy to require drug prices in TV ads

Facing progressive pressure, Pelosi could expand her drug pricing plan to negotiate prices for $118 billion worth of medicines

House votes to overturn Trump administration ban on fetal tissue research

House progressives challenge drug makers to come back to Capitol Hill

These Republicans campaigned on a bold drug-pricing pledge. Since they won, they’ve gone silent

A new Senate health package includes surprisingly aggressive drug pricing reforms

In Washington, a partisan approach to lowering drug costs leaves Democrats doubting their own party leadership

Joe Biden may resurface a long-held dream: a White House laser-focused on cancer